Biota Holdings (BTA-AU)

Benzinga  Mar 3  Comment 
Biota Pharmaceuticals, Inc. (Nasdaq: BOTA) announced today that it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir. The goal of the study is to enroll approximately 150 laboratory-confirmed human rhinovirus (HRV)...
GenEng News  Feb 26  Comment 
Biota Pharmaceuticals said today it will acquire Anaconda Pharma for up to $38 million, in a deal designed to grow the buyer’s infectious disease pipeline with a Phase II antiviral indicated for two diseases caused by human papillomavirus...

You may also be interested in articles related to Biota Holdings (BTA-AU):
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki